More recently, SphK/S1P/S1PR signalling modulators are being investigated for hard-to-treat and chemo-resistant pancreatic cancers to overcome intrinsic and acquired drug resistance [191,192,193,194]. This evidence concerns the gene MBTPS1 and pancreatic neoplasm.